Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has filed a lawsuit against ArcherDX, Inc. for the infringement of its U.S. Patent No. 10,731,220, issued on August 4, 2020. The lawsuit, filed in the U.S. District Court of Delaware, alleges that ArcherDX's oncology products violate Natera's patented methods related to DNA testing. This follows a prior suit filed against ArcherDX in January 2020 regarding four additional patents. Natera seeks both monetary damages and injunctive relief for these infringements.
Natera, Inc. (NASDAQ: NTRA) reported robust Q2 2020 results, processing approximately 234,100 tests, a 21% increase from Q2 2019. Total revenues reached $86.5 million, up from $74.4 million year-over-year. Gross profit rose to $39.5 million, achieving a 46% gross margin. However, the company faced an operating loss of $51.6 million compared to $28.6 million the previous year. Natera anticipates total 2020 revenues between $345 million and $365 million, with a projected cash burn of $125 million to $155 million.
Natera, Inc. (NASDAQ: NTRA) announced a validation of its Signatera™ circulating tumor DNA (ctDNA) technology in a study published in Nature Cancer. The research shows Signatera's effectiveness in assessing tumor response to immunotherapy across 25 solid cancer types. Key findings include ctDNA detection in 98% of cases before treatment and the ability to predict treatment non-response with 100% accuracy after just 6 weeks. The study highlights the clinical utility of ctDNA-based surveillance to distinguish true disease progression from pseudo-progression, addressing an unmet clinical need.
Natera, a leader in cell-free DNA testing, will announce its Q2 2020 financial results on August 5, 2020, after market close. A conference call is scheduled for 1:30 p.m. PT to discuss the results and future outlook. Natera's labs are certified under CLIA, providing essential genetic testing focused on women's health, oncology, and organ health. Investors can access a replay of the webcast at Natera's investor relations website.
Summary not available.
Natera, a leader in cell-free DNA testing, has expanded its laboratory facility in Austin, Texas, increasing its test processing capacity. The new 70,000 square foot facility features advanced automated equipment, which is expected to lower costs and improve operational continuity. Natera targets significant growth in markets exceeding a $25 billion dollar opportunity, having processed over three million medical tests to date. This expansion positions Natera to better serve patients and capitalize on future market demands.
Natera, Inc. (NASDAQ: NTRA) has announced the initiation of patient enrollment in two clinical trials: CIRCULATE-Japan and BESPOKE CRC. The CIRCULATE-Japan trial is a multi-center study with 2,500 participants focused on ctDNA-guided treatment strategies for resectable colorectal cancer (CRC) in Japan. Similarly, BESPOKE CRC aims to enroll over 1,000 patients, assessing the impact of blood-based testing for early relapse detection. Both trials highlight the growing interest and potential of Signatera technology, which may improve treatment outcomes for CRC patients globally.
Natera, Inc. (NASDAQ: NTRA) has filed a patent infringement lawsuit against Progenity, Inc. in the U.S. District Court for the Western District of Texas. The suit claims that Progenity's non-invasive prenatal test infringes on six patents held by Natera. These include U.S. Patents 9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,522,242. Natera is seeking both injunctive relief and monetary damages.